You just read:

Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting

News provided by

Mirati Therapeutics, Inc.

Nov 09, 2018, 08:35 ET